Adnkronos "The inclusion of genomic testing in the essential levels of care (LEA) represents an important step toward greater personalized breast cancer care. These tests," used in specific types of cancer, "help stratify the risk of endocrine-responsive, HER2-negative disease in the adjuvant setting. This is very important news, because we have the opportunity to test these patients and understand who truly needs chemotherapy and who does not" after surgery," said Giuseppe Curigliano, president-elect of the European Society of Medical Oncology, at the ESMO2026 congress in Madrid.
https://www.youtube.com/watch?v=4W2rN6qzokk
Continue on the app
The news of your city, in real time.
Open in app